Abstract: Provided is a use of mesenchymal stem cells in the preparation of a drug for repairing lung damage caused by COVID-19. It is proved by clinical tests for the first time that mesenchymal stem cells have an excellent effect on repair of lung damage in subjects with viral pneumonia, especially severe pneumonia caused by SARS-CoV-2 infection, and can significantly reduce solid component lesion volume of the subjects, and repair lung tissue; moreover, it is proved by means of a six minute walking test that mesenchymal stem cells can significantly repair the subjects' cardiopulmonary function, so that the aerobic exercise capacity is significantly improved, thereby effectively alleviating sequelae of the subjects after the end of antiviral treatment, and improving health and quality of life of the subjects; in addition, mesenchymal stem cells are highly safe, and no obvious adverse reactions have been found.

Abstract: A method for predicting the morphological changes of liver tumor after ablation based on deep learning includes: obtaining a medical image of liver tumor before ablation and a medical image of liver tumor after ablation; preprocessing the medical image of liver tumor before ablation and the medical image of liver tumor after ablation; obtaining a preoperative liver region map, postoperative liver region map, and postoperative liver tumor residual image map; obtaining a transformation matrix by a Coherent Point Drift (CPD) algorithm and obtaining a registration result map according to the transformation matrix; training the network by a random gradient descent method to obtain a liver tumor prediction model; using the liver tumor prediction model to predict the morphological changes of liver tumor after ablation. The method provides the basis for quantitatively evaluating whether the ablation area completely covers the tumor and facilitates the postoperative treatment plan for the patient.

Abstract: The invention discloses a method for constructing functional exosomes capable of efficiently loading specific miRNA. In order to enable the exosome to carry miRNA with specific regulation function more efficiently so as to play a role in targeted regulation more accurately and efficiently, MS2 phage capsid protein is utilized to edit and construct a capture element of a specific miRNA molecule, and placenta mesenchymal stem cells are reprogrammed to enable the secreted exosome to efficiently load a target miRNA molecule, so that the target miRNA molecule is delivered to tissue cells to play a role in effective regulation, and therefore a new strategy is provided for realizing specific precise treatment in the future.

Abstract: An energy-saving portable dryer for digestive endoscope is disclosed, including a box and a top cover. The box is a hollow shell structure, and the top cover covers the upper port of the box to form a sealed environment. The upper end of the top cover is provided with a controller to control the operation of the device. The box is internally provided with heating tubes. The box is provided with a water inlet and drainage mechanism. The bottom end of the box is provided with a liquid heater to heat the disinfection solution in the box to generate hot vapor. The top cover and the box are installed and disassembled through a fixed mechanism. The energy-saving portable dryer for digestive endoscope has the characteristics of energy saving and high efficiency. And its effect of disinfection and sterilization is better, which increases the practicability.

Abstract: A method for predicting the morphological changes of liver tumor after ablation based on deep learning includes: obtaining a medical image of liver tumor before ablation and a medical image of liver tumor after ablation; preprocessing the medical image of liver tumor before ablation and the medical image of liver tumor after ablation; obtaining a preoperative liver region map, postoperative liver region map, and postoperative liver tumor residual image map; obtaining a transformation matrix by a Coherent Point Drift (CPD) algorithm and obtaining a registration result map according to the transformation matrix; training the network by a random gradient descent method to obtain a liver tumor prediction model; using the liver tumor prediction model to predict the morphological changes of liver tumor after ablation. The method provides the basis for quantitatively evaluating whether the ablation area completely covers the tumor and facilitates the postoperative treatment plan for the patient.

Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.

Abstract: An intelligent monitoring system for pelvic fracture reduction, comprising a sample fracture model database, a patient pelvic fracture data acquisition unit, a reduction situation monitoring unit and a mixed reality data fusion processing unit, the sample fracture model database stores a plurality of sample fracture models, the patient pelvic fracture data acquisition unit uses magnetic navigation and positioning technology to collect patient pelvic location information data in real-time and upload it to the mixed reality data fusion processing unit, the mixed reality data fusion processing unit automatically invokes the sample fracture model in the sample fracture model database corresponding to patient pelvic fracture condition and matches the patient pelvic location information data with the sample fracture model using mixed reality technology to form an intelligent fracture model for the patient's pelvic fracture state, the reduction situation monitoring unit loads and displays images of the intelligent f

Abstract: Provided is use of a recombinant nucleic acid construct containing a B7-2-PE40 exotoxin fusion gene in the preparation of a DNA vaccine or medicament for treatment and/or prevention of type 1 diabetes. The DNA vaccine can reduce blood glucose in patient with type 1 diabetes, restore the secretion of insulin of the patients per se, and reduce the contents of islet cell autoantibody (ICA) and glutamate decarboxylase autoantibody (GAD) in the patients.

Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.

Abstract: The present disclosure provides application of a compound in conformity with a general formula I, and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating and/or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease or a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis

Abstract: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.

Abstract: The apparatus and method of the present invention are used to detect the ECG and/or blood pressure (BP) waveforms and measure the R-R and Q-T intervals from the detected ECG signals, so as to determine the pulse structure of the heart stimulating signals, and to stimulate the heart. The heart is stimulated by the stimulating signals which includes a pacing pulse train applied to atrium for forming an artificial heart rhythm, and an inducing pulse train applied to ventricle for introducing ME or VT waveforms. By adjusting the time location and amplitude of the inducing pulses relative to the pacing pulses, the ME or VT waveforms are induced in the ECG signals. By detecting the ECG and/or BP waveforms, the ME or VT is identified and at the same time the heart stimulation is stopped. Then the induced ME or VT waveforms and the amplitude of the inducing pulse which induces the ME or VT waveforms are displayed and the ventricular fibrillation threshold is derived according to this amplitude.